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BACKGROUND: Glomeruloid microvascular proliferation (GMP), a novel histology-based angiogenesis marker, has been associated with
decreased survival in several human cancers.
METHODS: In this study, we evaluated the ability of GMP to predict clinical response to neoadjuvant chemotherapy in a series of locally
advanced breast cancers (n¼112).
RESULTS: Presence of GMP (21% of the cases) was significantly associated with high-grade tumours and TP53 mutations in addition to
the basal-like and HER2 subtypes of breast cancer as defined by gene expression data. GMP was correlated to a gene expression
signature for tumour hypoxia response. The GMP pattern was also significantly associated with lack of treatment response and
progressive disease (P¼0.004).
INTERPRETATION: The findings suggest that GMP might be able to predict the lack of response to neoadjuvant chemotherapy in locally
advanced breast cancer. Whether GMP may be an independent predictor compared with other factors including TP53 mutation
status and tumour grade needs confirmation in larger studies.
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Angiogenesis is important for the growth and spread of malignant
tumours (Carmeliet, 2003). Although vascular density has been
correlated to survival in different malignancies (Weidner et al,
1991, 1992; Hlatky et al, 2002; Uzzan et al, 2004), angiogenesis
markers have not been associated with response to chemotherapy
or anti-angiogenesis treatment (Paulsen et al, 1997; Tynninen et al,
2002; Jubb et al, 2006). Glomeruloid microvascular proliferations
(GMP), a novel angiogenesis marker, are focal aggregates of small
vessels resembling a renal glomerulus (Pettersson et al, 2000;
Sundberg et al, 2001). In mice, GMP has been induced by local
injection of an adenovirus vector directing VEGF-A expression
(Sundberg et al, 2001). A human parallel appears to be the POEMS
syndrome, where increased VEGF-A is associated with glomeruloid
haemangiomas (Tsai et al, 2001). In humans, GMP is a defining
histological feature of glioblastoma multiforme (Wesseling et al,
1993; Schiffer et al, 1999) and a prognostic factor in several other
tumours (Straume et al, 2002; Tanaka et al, 2003; Foulkes et al,
2004). In this study of locally advanced breast cancer, GMP showed
a significant association with lack of treatment response and
progressive disease following chemotherapy.
PATIENTS AND METHODS
Patients
The patients included in this study were all treated in two
prospective single-arm studies for locally advanced breast cancer
(T3/T4 and/or N2 tumours) at the Department of Oncology,
Haukeland University Hospital (Bergen, Norway). Briefly, in the
first study (carried out during 1991–1996), each patient (n¼94;
median age 64 yrs) received doxorubicin monotherapy adminis-
tered at a dose of 14mgm
 2 on a weekly basis (Aas et al, 1996;
Geisler et al, 2001). In the second study (carried out during
1993–2000), 35 patients (median age 67 years) received 5-FU
1000mgm
 2 on day 1 and 2 with mitomycin 6mgm
 2 day 2 at
3-weekly intervals (Geisler et al, 2003). Patients were recruited
by the same clinical criteria, with no selection, and tissue was
obtained by open surgical biopsy. Clinical responses were
classified as complete response (CR), partial response (PR),
progressive disease (PD), and stable disease (SD) according
to the UICC criteria generally applied at the time period these
clinical studies were conducted (Hayward et al, 1977). Tumour
size in general was measured with use of calipers on a 4-weekly
(doxorubicin protocol) or 3-weekly basis (5FU/mitomycin protocol).
In case a PD was recorded (25% increase in the product of
perpendicular diameters), the patient immediately terminated
this chemotherapy and was allocated for an alternative treatment
option. For internal consistency, we compared tumours with PD
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swith the combined group of SD/PR/CR, similar to what was
conducted in our previous reports from the same materials
(Geisler et al, 2001, 2003).
Basic variables and immunohistochemistry
Histological type and histological grade (Elston and Ellis, 1991)
were recorded, as well as lymph node status. Staining of endo-
thelial cells by Factor-VIII antibody A-0082 (Dako, Copenhagen,
Denmark) was performed on paraffin-embedded archival material
(Straume et al, 2002). Of a total of 129 cases, sufficient tissue
for reliable analysis was available in 112 cases; one histo-
logical slide was examined from each case with selection of
the highest tumour grade in case of heterogeneity. Positivity
for GMP was recorded on the initial surgical biopsy by one
observer (OS) and defined as the presence of focal glomerulus-like
aggregates of closely associated and multilayered Factor-VIII-
positive endothelial cells (Pettersson et al, 2000; Sundberg et al,
2001; Straume et al, 2002). Recorded GMPs or ‘glomeruloid bodies’
typically consisted of 15–100 cells. Glomeruloid microvascular
proliferation status was reported as absent or present (one GMP
was sufficient to define the case as positive; in most cases more
GMPs were observed).
Mutations and gene expression
Mutations in the TP53 gene (exons 2–11) were analysed using
genomic DNA and TTGE (temporal temperature gradient gel
electrophoresis) as reported (Aas et al, 1996; Geisler et al, 2001).
Microarray data were available from previous studies in 78 cases
(Perou et al, 2000; Sorlie et al, 2001, 2003), and analysis of a
hypoxia-related expression signature was carried out (Chi et al,
2006). The hypoxia signature reflects the most differentially
expressed genes in epithelial cells after hypoxia in vitro (mammary
epithelial cells and renal tubular cells).
Statistical analysis
Associations between different categorical variables were evaluated
by Pearson’s w
2-test, Fisher’s exact test or McNemar’s test.
Statistical significance was assessed at the two-sided 5% level.
Prediction of disease progression was analysed by logistic
regression. The data were analysed using the SPSS version 15.0
statistical software (SPSS Inc., Chicago, IL, USA).
RESULTS
Glomeruloid microvascular proliferation positivity was present in
24 of 112 primary tumours (21%) (Table 1). In 56 cases with tissue
available after chemotherapy, the frequency of GMPþ increased
from 16 to 32% (McNemar’s test, P¼0.035). Regarding histolo-
gical features, 25% of ductal carcinomas were GMPþ, compared
with 0% of non-ductal tumours (Fisher’s exact test, P¼0.038).
Glomeruloid microvascular proliferation positivity was associated
with histological grade (frequency of 0, 14 and 40% in grades 1–3,
respectively; P¼0.001) and lymph node status in particular
(pN0–1: 12% GMPþ, pN2: 38% GMPþ; P¼0.011) (Table 1).
Glomeruloid microvascular proliferation positivity was signifi-
cantly associated with lack of response to treatment (PD). Of 17
cases with PD, GMPþ was found in eight cases (47%), compared
with 16% among the rest (Pearson’s w
2-test, P¼0.004). Conversely,
35% of GMPþ cases showed progressive disease, compared with
10% among GMP  cases (P¼0.004). Further, there was a strong
association between GMPþ and TP53 mutation status (TP53
mutated tumours, 38% GMPþ; wtTP53 tumours, 11% GMPþ;
w
2¼11.1, P¼0.001). This association persisted when mutations
in the L2/L3 domain were compared with other mutations and
wild-type tumours combined (w
2¼8.8, P¼0.003). However, GMPþ
was also observed in TP53 wild-type cases (n¼69) and tended to
show an association with progressive disease within this subgroup:
two GMP positive of six in the PD group (33%) vs five GMP
positive of 63 (8%) among the others; Pearson’s w
2-test: P¼0.049;
Fisher’s exact test: P¼0.11. Logistic regression analysis revealed
TP53 mutations (wild type and non-L2/L3 vs L2/L3 mutations) to
predict disease progression independently (P¼0.005) (Aas et al,
1996; Geisler et al, 2003), whereas GMP status showed an
independent association with disease progression of borderline
significance (P¼0.07). When cases with either TP53 mutation
(L2/L3 type) or GMPþ were combined, there was a highly signi-
ficant association with disease progression (PD) (P¼0.001).
When looking at gene expression patterns in relation to GMP
status (78 cases available from the doxorubicin-treated series),
statistical analysis of microarrays (SAM) between GMP-positive
and -negative tumours revealed that 76 genes were significantly
downregulated in GMP-positive cases (none were significantly
upregulated; false discovery rate 20%), five of these genes more
than twofold: NAT1 (N-acetyltransferase 1), ESR1 (estrogen
receptor 1), TFF3 (trefoil factor 3), PLAT (plasminogen activator,
tissue), and HIST2H2BE (histone cluster 2, H2BE). Of these, two
genes (TFF3, PLAT) have been involved in angiogenesis regulation.
Glomeruloid microvascular proliferation was also associated
with a hypoxia-related gene expression signature, which was
Table 1 Associations between GMP status and important tumour
characteristics, as well as treatment response
GMP present GMP absent
Variables No. % No. % P-value
a
Histological type 0.038
Ductal 24 25 73 75
Others 0 0 15 100
Histological grade 0.001
Grade 1 0 0 17 100
Grade 2 7 13 45 87
Grade 3 17 40 26 60
Lymph node status 0.011
N0 5 15 28 85
N1 5 12 37 88
N2 14 38 23 62
TP53 mutations 0.001
Absent 8 11 62 89
Present 16 38 26 62
Hypoxia signature 0.041
Negative 10 20 40 80
Positive 12 41 17 59
Molecular subtype
b 0.040
c
Luminal A 5 15 28 85
Luminal B 3 23 10 77
HER2 8 44 10 56
Basal-like 4 33 8 67
Normal-like 1 50 1 50
Clinical response
d 0.004
Non-PD 15 16 79 84
PD 8 47 9 53
Abbreviations: GMP¼glomeruloid microvascular proliferation; PD¼progressive
disease.
aP-value by Pearson’s w
2-test or Fisher’s exact test;
bMolecular subtype is
based on microarray data (from Perou et al, 2000; Sorlie et al, 2001, 2003);
cBasal-like
and HER2 tumours combined were compared with the rest;
dNon-PD is a
combination of complete response, partial response, and stable disease.
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spresent in 37% of all tumours and more frequent in GMP-positive
cases (55%) when compared with GMP-negative tumours (30%)
(P¼0.041). Positivity for the hypoxia signature was significantly
associated with basal-like tumours (83% compared with 29%
among the others; P¼0.0003; the signature was positive in only
3% of luminal A cases).
The GMP frequency was increased among the aggressive basal-
like and HER2 subgroups of breast cancer based on gene
expression data on these cases (GMP frequency: basal-like 33%,
HER2 44%, luminal-A 15%, luminal-B 23%; P¼0.040) (Perou et al,
2000; Sorlie et al, 2001).
DISCUSSION
Our findings indicate an association between GMP and lack of
clinical response to neoadjuvant chemotherapy in a series of
locally advanced breast cancers. In previous studies, no relation-
ship between standard microvessel density and treatment response
was observed (Paulsen et al, 1997; Tynninen et al, 2002; Jubb et al,
2006). Here, GMP was significantly correlated to the presence of
TP53 mutations, which might be pathogenetically involved in this
angiogenic phenotype (Dameron et al, 1994; Foulkes et al, 2004).
Previous studies have implicated TP53 in angiogenesis regulation
through mechanisms involving TSP-1, bFGF-binding protein,
HIF-1a and VEGF (Dameron et al, 1994; Ravi et al, 2000; Zhang
et al, 2000; Sherif et al, 2001; Pore et al, 2004). However, GMP was
also observed in mutation-negative tumours, indicating that TP53
could represent one of several possible pathways. As the hypoxia
signature was more frequent in GMP-positive tumours, GMP
formation might be stimulated by hypoxia-related pathways, like
HIF-1a activation and increased VEGF expression. Taken together,
our findings suggest that TP53 mutations and tumour hypoxia may
both be related to the pathogenesis of this angiogenic phenotype in
human breast cancer.
Interestingly, in a subset of the cases where tissue was available
for study after treatment, the frequency of GMP was significantly
increased (from 16% among the initial biopsies to 32% post-
treatment in paired samples). It is not clear, however, whether this
reflects a sampling effect or a selection of more aggressive and
treatment resistant tumour components.
In summary, a significant association between GMP and lack of
response to neoadjuvant chemotherapy in locally advanced breast
cancer is indicated. Future studies are needed to assess the
potential predictive value of GMP for targeted anti-angiogenesis
treatment in breast cancer and other tumours.
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